P Jakobs
Overview
Explore the profile of P Jakobs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
326
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jakobs P, Schulz P, Ortmann C, Schurmann S, Exner S, Rebollido-Rios R, et al.
Sci Rep
. 2016 May;
6:26435.
PMID: 27199253
Decision making in cellular ensembles requires the dynamic release of signaling molecules from the producing cells into the extracellular compartment. One important example of molecules that require regulated release in...
2.
Zipp F, Hartung H, Hillert J, Schimrigk S, Trebst C, Stangel M, et al.
Neurology
. 2006 Nov;
67(10):1880-3.
PMID: 17130431
We assessed the safety and efficacy of orally administered CC chemokine receptor 1 (CCR1) antagonist in 105 patients with relapsing/remitting MS (RRMS) in a 16-week, randomized, double-blind, placebo-controlled trial. The...
3.
Kappos L, Polman C, Freedman M, Edan G, Hartung H, Miller D, et al.
Neurology
. 2006 Aug;
67(7):1242-9.
PMID: 16914693
Objective: To assess efficacy, safety, and tolerability of every-other-day interferon beta-1b treatment in patients with a first clinical event suggestive of multiple sclerosis (MS) (clinically isolated syndrome). Methods: We conducted...
4.
Polman C, Barkhof F, Kappos L, Pozzilli C, Sandbrink R, Dahlke F, et al.
Mult Scler
. 2003 Aug;
9(4):342-8.
PMID: 12926838
Background: Interferon beta (IFNB) is available in parenteral formulations for treatment of multiple sclerosis (MS). The purpose of this study was to evaluate safety, tolerability and effects on MRI lesions...
5.
Pulsipher M, Kupfer G, Naf D, Suliman A, Lee J, Jakobs P, et al.
Mol Med
. 1998 Aug;
4(7):468-79.
PMID: 9713825
Fanconi anemia (FA) is an autosomal recessive cancer susceptibility syndrome with at least eight complementation groups (A-H). Two of the FA genes (FAA and FAC) have been cloned, and mutations...
6.
7.
Swart E, Bohlert I, Jakobs P, Robra B, Schneider F, Leber W, et al.
Gesundheitswesen
. 1996 Jan;
58(1):10-5.
PMID: 8851126
Problem: Performance of an analysis of hospitalised cases based on processed statutory health insurance data on inpatient treatments. Object of the examination were regional differences in the frequency of hospitalisation...
8.
Quan F, Grompe M, Jakobs P, Popovich B
Hum Mol Genet
. 1995 Sep;
4(9):1681-4.
PMID: 8541863
No abstract available.
9.
Whitney M, Jakobs P, KABACK M, Moses R, Grompe M
Hum Mutat
. 1994 Jan;
3(4):339-41.
PMID: 8081385
Fanconi anemia (FA) is an autosomal recessive disease for which at least four complementation groups exist. Recently the gene that corrects the defect in Fanconi anemia complementation group C cells...
10.
Coan C, Jakobs P, Ji J, Murphy A
FEBS Lett
. 1993 Nov;
335(1):33-6.
PMID: 7902300
The sarcoplasmic reticulum Ca(2+)-ATPase loses hydrolytic activity and the ability to be phosphorylated by Pi following incubation with EDC [1-ethyl-3-(3-dimethylaminopropyl)carbodiimide]. 4 nmol of tempamine per mg SR protein can be...